Investigational drug · Phase 3
LMN-201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Clostridioides Difficile Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "LMN-201"
First trial start
2024
Aug 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LMN-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Clostridioides Difficile Infection
Approved drugs for the same conditions: C. difficile infection · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "LMN-201" as an intervention, largest first.
- LMN-201 for Prevention of C. Difficile Infection RecurrencePivotal-lookingActive, not recruiting
Lumen Bioscience, Inc.Industry
NCT05330182 · 375 participants (planned) · Start Aug 29, 2024 · Primary completion Aug 31, 2026
Drug: LMN-201; Placebo · For: Clostridioides Difficile Infection
Sites: Escondido, California; Hamden, Connecticut; Tampa, Florida · 15 sites in all
Lumen Bioscience, Inc.Industry
NCT04893239 · 12 participants · Start Aug 18, 2021 · Primary completion Feb 23, 2022
Drug: LMN-201 Anti-toxin B VHH-1; LMN-201 Anti-toxin B VHH-2 and 2 more · For: C. Diff. Infections
Sites: Auchenflower, Australia; Maroochydore, Australia; North Mackay, Australia
Newest research
PubMed records naming it or its code names, newest first.
- New investigational agents for the treatment of Clostridioides difficile infections.
Tran MN, Eubank TA, Kullar R, et al. · Expert Opin Investig Drugs 2025
- The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects.
Alshrari AS, Hudu SA, Elmigdadi F, et al. · Biomedicines 2023
Also in development for Clostridioides Difficile Infection
- VE303Phase 31 trial
Vedanta Biosciences, Inc. · Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence
- AZD5148Phase 21 trial
AstraZeneca · Clostridioides Difficile Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.